Medical Device

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) clearance of patient-specific UNiD™ Rods for use with Medtronic CD Horizon™ Solera™ Voyager™ and Infinity™ OCT spinal systems, expanding the utility of the company's UNiD™ Adaptative Spine Intelligence (ASI) technology. UNiD Rods are designed for each patient and industrially pre-bent prior to surgery to accurately match an artificial intelligence (AI)-driven pre-operative surgical plan, which is created with UNiD™ ASI technology to precisely align patients' spines 1 ,2 , reducing the risk of malalignment and associated revision surgeries. 3 UNiD Rods are used to treat scoliosis, trauma, tumors, and complex degenerative conditions in adults and adolescent idiopathic scoliosis.

Spine surgery is one of the more complex procedures in healthcare because of the high number of different parameters that must be taken into consideration. In conventional spine surgery, surgeons manually bend spine rods in the operating room, and there can be large variability in outcomes. With the compatibility of UNiD Rods and Medtronic's spinal systems, surgeons are able to tailor rods, as well as select the Medtronic interbody devices and other hardware that are best suited for their patient's unique anatomy and sagittal alignment needs. Additionally, surgeons can use advanced navigation and robotics, like the Mazor™ Robotic Guidance System, with minimally invasive patient-specific rods to make procedures more precise and efficient and improve surgical outcomes.

The first surgery combining the CD Horizon Solera Voyager minimally invasive spinal system with patient-specific UNiD Rods in combination with the Mazor platform was performed by Dr. Gregory Poulter , OrthoIndy Hospital, Indianapolis, Ind.

"Being able to integrate powerful complimentary technologies -- AI, robotics and patient-specific implants -- is the future of spine surgery and will change spine care for the better by streamlining my workflow and reducing surgical uncertainty," said Dr. Poulter. "I'm not bending rods or increasing OR time with manual execution. Instead, I planned my first case with AI, selected the best hardware for my patient, executed the surgery with Mazor robotic-assisted delivery of the screws and was able to position the rod in 2.5 minutes, resulting in less blood loss and OR time and, most importantly, a predictable and precise alignment for my patient."

Spine surgery is evolving and becoming increasingly personalized. It is no longer just driven by metal implants and instrumentation, but advanced imaging, navigation, robotics, and pre-operative planning aided by AI. UNiD™ Adaptive Spine Intelligence provides a planning service powered by AI, intra-operative execution, and insightful analytics of surgical results with the ultimate goal of improving clinical outcomes. This game changing solution is easily accessible to any surgeon via a user-friendly UNiD™ HUB platform.

"By combining our widely used spinal systems with UNiD Rods, Medtronic is putting surgeons on the forefront and revolutionizing spine care as the first company to offer a fully integrated solution with unparalleled technologies - AI-driven surgical planning, personalized spinal implants and robotic assisted surgical delivery that work together to advance patient care," said Dan Wolf , vice president, Medicrea, within the Cranial & Spinal Technologies business, which is part of the Neuroscience Portfolio at Medtronic. "The next era of spine care is in personalized care that integrates the most advanced technologies to offer optimal planning, precision and predictability, so surgeons can do more for their patients."

About UNiD™ ASI Platform
The UNiD ASI platform uses a database of thousands of surgical cases to power algorithms that visualize multiple permutations, allowing surgeons to better understand their patients alignment before surgery, customize a surgical plan with highly qualified UNiD™ LAB biomedical engineers and use a patient-specific rod industrially bent in the optimal plane to help ensure the goals of the surgery are achieved. AI helps visualize mechanisms above and below the spine that will most likely occur based on the surgical plan in order to enhance clinical and surgical workflow, increase reproducibility, improve surgical outcomes.

About the CD Horizon™ Solera™ Voyager™ and Infinity™ OCT Spinal Systems
These systems help provide immobilization and stabilization of spinal segments. The systems consists of a variety of screws and other implant components that can be rigidly locked into a variety of configurations, with each construct being tailor-made for the patient's unique anatomy and sagittal alignment needs.

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services, and solutions companies – alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1 Cameron Barton BA, Andriy Noshchenko PhD, Vikas Patel MD, Christopher Kleck MD, Evalina Burger MD. Early Experience and Initial Outcomes with Patient Specific Spine Rods for Adult Spinal Deformity (ASD). Orthopedics. 2016; 39(2):79-86.
2 Kuris, Eren, et al. "Analysis of Radiographic Parameters Reveals Differences in Outcomes When Comparing Patient-Specific Short Rod Constructs to Conventional Rods in Lumbar Fusions for Degenerative Disease." International Meeting on Advanced Spine Technologies. 2020.
3 Rothenfluh DA, Mueller DA, et al. Pelvic incidencelumbar lordosis mismatch predisposes to adjacent segment disease after lumbar spinal fusion. Eur Spine J (2015) 24:1251-1258

Contacts:




Kyra Nead

Ryan Weispfenning

Public Relations

Investor Relations

+1-303-886-2549

+1-763-505-4626

Medtronic plc (PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/medtronic-gains-fda-clearance-of-unid-patient-specific-rods-for-use-with-cd-horizon-solera-voyager-and-infinity-oct-spinal-systems-301304750.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 20 th Annual Global Healthcare Conference on Wednesday, September 14 th , at the Sheraton New York Hotel in New York. Joaquin Duato, Chief Executive Officer, and Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS

  • Revenues of $1.967 billion
  • Company to appeal anticipated court decision and vigorously defend XIFAXAN intellectual property
  • Balance sheet continues to improve with early retirement of $481 million of long-term debt through open market repurchases
  • Committed to strategic alternatives and will continue to evaluate the distribution of Bausch + Lomb shares as the Company works through patent litigation
  • Updates guidance

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second-quarter 2022 financial results.

"The second quarter was a transitional quarter for Bausch Health as we intensified our focus on the Bausch Pharma and Solta businesses," Thomas J. Appio , Chief Executive Officer, Bausch Health , said. "In our first ninety days, our leadership team has taken immediate action to strengthen execution and accelerate change. We have advanced debt paydown through open market repurchases this quarter. We are focused on creating value through driving growth, profitability and improving our balance sheet."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) ("the Company") announced today that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is identified.

Dr. Mammen joined Johnson & Johnson in 2017 as Global Head of Janssen R&D, and the Company thanks Dr. Mammen for his contributions in advancing Johnson & Johnson's industry-leading portfolio. The Company will continue to prioritize innovation and building new capabilities to improve the lives of the patients and consumers we serve worldwide.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Avricore Health

Healthtab™ Expands With Shoppers Drug Mart®

AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is pleased to announce that the Company is significantly expanding the number of Shoppers Drug Mart pharmacies offering its HealthTab point-of-care testing platform under a renewed Master Service Agreement (MSA) to up to 450 locations nation-wide.

In addition to Shoppers Drug Mart pharmacies, this new MSA and corresponding Statement of Work (SOW) provides for affiliated locations under the Loblaw family of brands, to utilize HealthTab upon request.

Keep reading...Show less

Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals

  • Two industry leaders join forces to empower people living with diabetes by providing information and insights to improve weight loss, glucose control and overall health
  • Collaboration will create a seamless, integrated experience between Abbott's world-leading continuous glucose monitoring device 1 and WeightWatchers' number one doctor-recommended weight loss program 2 to help individuals better understand and manage their diabetes and weight

Abbott (NYSE: ABT) and WW International, Inc. ("WeightWatchers" or "WW") today announced a strategic partnership that will help people living with diabetes better understand and manage their diabetes and weight. The companies are working together to integrate WeightWatchers' diabetes-tailored weight management program with Abbott's portfolio of FreeStyle Libre ® products to create a seamless mobile experience that will give people living with diabetes the information and insights needed to make healthy adjustments to their diet, improve their glucose levels, and, ultimately, gain more control of their health.

Maintaining a healthy body weight and having proper nutrition are critical to living well with diabetes. 3 Yet, for many people living with diabetes, determining what to eat and following a meal plan is the most challenging part of diabetes management. 4 Through this partnership, participants can receive glucose insights from Abbott's FreeStyle Libre sensor-based technology that show the impact of food choices, alongside the empirically validated 5 WeightWatchers' diabetes-tailored nutritional guidance to help them achieve their healthier living goals.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Second Quarter 2022 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2022 financial results on Thursday, August 11, 2022 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, August 11, 2022

Time : 8:30 a.m. ET

Telephone : Toll Free: 1-855-669-9657 or International 1-412-317-0790

Webcast : www.gud- knight .com or Webcast
This is a listen-only audio webcast. Media Player is required to listen to the broadcast.

Replay : An archived replay will be available for 30 days at www.gud-knight.com .


________________________________________
About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×